$SEEL
Seelos Therapeutics Inc Stock $seel

$seel Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000101749114000070 Filed on May 12, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$0.00	$929.0K
YoY Change	-100.0%	38.86%
Cost Of Revenue	$0.00	$1.847M
YoY Change	-100.0%	2330.26%
Gross Profit	$0.00	-$922.0K
YoY Change	-100.0%	-237.82%
Gross Profit Margin		-99.25%
Selling, General & Admin	$3.060M	$3.830M
YoY Change	-20.1%	-4.08%
% of Gross Profit
Research & Development	$1.444M	$1.413M
YoY Change	2.19%	20.05%
% of Gross Profit
Depreciation & Amortization	$20.00K	$21.00K
YoY Change	-4.76%	-78.57%
% of Gross Profit
Operating Expenses	$3.543M	$5.239M
YoY Change	-32.37%	18.61%
Operating Profit	-$3.543M	-$6.161M
YoY Change	-42.49%	65.98%
Interest Expense	-$107.0K	-$231.0K
YoY Change	-53.68%	-233.14%
% of Operating Profit
Other Income/Expense, Net	$281.0K	-$789.0K
YoY Change	-135.61%	-1853.33%
Pretax Income	-$3.260M	-$6.950M
YoY Change	-53.09%	87.84%
Income Tax
% Of Pretax Income
Net Earnings	-$3.262M	-$8.673M
YoY Change	-62.39%	84.02%
Net Earnings / Revenue		-933.58%
Basic Earnings Per Share	-$0.09
Diluted Earnings Per Share	-$0.09	-$78.82M
COMMON SHARES
Basic Shares Outstanding	37.90M shares	30.34M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.49M	$14.10M
YoY Change	59.5%	-34.51%
Cash & Equivalents	$22.49M	$14.10M
Short-Term Investments
Other Short-Term Assets	$620.0K	$980.0K
YoY Change	-36.73%	145.0%
Inventory	$364.0K
Prepaid Expenses
Receivables	$69.00K	$499.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$23.54M	$15.58M
YoY Change	51.07%	-32.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.360M	$615.0K
YoY Change	121.14%	-85.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$93.00K	$98.00K
YoY Change	-5.1%	-78.71%
Total Long-Term Assets	$1.453M	$1.045M
YoY Change	39.04%	-88.06%
TOTAL ASSETS
Total Short-Term Assets	$23.54M	$15.58M
Total Long-Term Assets	$1.453M	$1.045M
Total Assets	$24.99M	$16.63M
YoY Change	50.31%	-47.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$990.0K	$1.850M
YoY Change	-46.49%	150.0%
Accrued Expenses	$1.979M	$3.734M
YoY Change	-47.0%	51.65%
Deferred Revenue
YoY Change
Short-Term Debt	$2.660M	$1.410M
YoY Change	88.65%	-64.75%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.58M	$10.17M
YoY Change	43.38%	2.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$3.390M
YoY Change	-100.0%	16850.0%
Other Long-Term Liabilities	$80.00K	$218.0K
YoY Change	-63.3%	122.84%
Total Long-Term Liabilities	$80.00K	$218.0K
YoY Change	-63.3%	122.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.58M	$10.17M
Total Long-Term Liabilities	$80.00K	$218.0K
Total Liabilities	$14.66M	$17.24M
YoY Change	-14.95%	47.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$271.3M	-$259.8M
YoY Change	4.44%	15.95%
Common Stock	$280.2M	$258.5M
YoY Change	8.41%	5.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.890M	-$609.0K
YoY Change
Total Liabilities & Shareholders Equity	$24.99M	$16.63M
YoY Change	50.31%	-47.84%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$3.262M	-$8.673M
YoY Change	-62.39%	84.02%
Depreciation, Depletion And Amortization	$20.00K	$21.00K
YoY Change	-4.76%	-78.57%
Cash From Operating Activities	-$192.0K	-$6.770M
YoY Change	-97.16%	31.22%
INVESTING ACTIVITIES
Capital Expenditures	$355.0K	$37.00K
YoY Change	859.46%	85.0%
Acquisitions
YoY Change
Other Investing Activities	$50.00K	$4.870M
YoY Change	-98.97%	-1973.08%
Cash From Investing Activities	-$305.0K	$4.830M
YoY Change	-106.31%	-1824.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.641M	$791.0K
YoY Change	107.46%	-95.94%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.583M	790.0K
YoY Change	100.38%	-95.96%
NET CHANGE
Cash From Operating Activities	-$192.0K	-6.770M
Cash From Investing Activities	-$305.0K	4.830M
Cash From Financing Activities	$1.583M	790.0K
Net Change In Cash	$1.086M	-1.150M
YoY Change	-194.43%	-108.16%
FREE CASH FLOW
Cash From Operating Activities	-$192.0K	-$6.770M
Capital Expenditures	$355.0K	$37.00K
Free Cash Flow	-$547.0K	-$6.807M
YoY Change	-91.96%	31.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	926000	USD
CY2014Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	992000	USD
CY2014Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	69000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59000	USD
CY2013Q1	us-gaap	Accretion Expense AccretionExpense	90000	USD
CY2014Q1	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2013Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	68000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21405000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2119000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1979000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	997000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15130000	USD
CY2014Q1	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	59000	USD
CY2014Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	526000	USD
CY2013Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	952000	USD
CY2013Q4	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	168000	USD
CY2014Q1	us-gaap	Accrued Environmental Loss Contingencies Current AccruedEnvironmentalLossContingenciesCurrent	174000	USD
CY2014Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	595000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	280180000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	279000000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	700000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	491000	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	100000	USD
CY2013Q4	us-gaap	Assets Assets	23310000	USD
CY2014Q1	us-gaap	Assets Assets	24994000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	22264000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	23541000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22491000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14104000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1026000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1086000	USD
CY2013Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	1500000	USD
CY2014Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
CY2013Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-725000	USD
CY2014Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	0	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37541404	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37855072	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37855072	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37541404	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	38000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	38000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8595000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3262000	USD
CY2014Q1	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	882000	USD
CY2013Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2600000	USD
CY2014Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2659000	USD
CY2014Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2659000	USD
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2600000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4000	USD
CY2013Q1	us-gaap	Cost Of Services CostOfServices	1847000	USD
CY2014Q1	us-gaap	Cost Of Services CostOfServices	0	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1250000	USD
CY2014Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2750000	USD
CY2014Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2750000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2750000	USD
CY2014Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	91000	USD
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	150000	USD
CY2013	us-gaap	Debtor Reorganization Items Write Off Of Deferred Financing Costs And Debt Discounts DebtorReorganizationItemsWriteOffOfDeferredFinancingCostsAndDebtDiscounts	200000	USD
CY2013Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	487000	USD
CY2014Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	444000	USD
CY2013Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	184000	USD
CY2014Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	166000	USD
CY2014Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5454000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1800000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21000	USD
CY2014Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	124000	USD
CY2013Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	517000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	126000	USD
CY2014Q1	us-gaap	Escrow Deposit EscrowDeposit	300000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-393000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	517000	USD
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	124000	USD
CY2013Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2014Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	910000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	50000	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	0	USD
CY2014Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	900000	USD
CY2013Q1	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	0	USD
CY2014Q1	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	50000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3826000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3059000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	0	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	-922000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6950000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3262000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.23
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.09
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1723000	USD
CY2014Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2013Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.06
CY2014Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	0.00
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	67000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-394000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-116000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-17000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-203000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	113000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-468000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-95000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-43000	USD
CY2013Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	631000	USD
CY2014Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-393000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-11000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	32000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	103000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2013Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	291000	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-107000	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-231000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2014Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	364000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	336000	USD
CY2014Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	237000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	209000	USD
CY2014Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	127000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	127000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23310000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24994000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11760000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	14580000	USD
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2013Q1	us-gaap	Licenses Revenue LicensesRevenue	32000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	0	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	775000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	791000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1583000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3329000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-305000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6047000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-192000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-3262000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-8673000	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	70000	USD
CY2013Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	281000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-789000	USD
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	3543000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	5239000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6161000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3543000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	472000	USD
CY2014Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	529000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	93000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	91000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	78000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	91000	USD
CY2013Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	4000	USD
CY2014Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	388000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-558000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	355000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	37000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	235000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	132000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1641000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	791000	USD
CY2013Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	0	USD
CY2014Q1	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-50000	USD
CY2013	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	8000000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3657000	USD
CY2014Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	50000	USD
CY2013Q1	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	0	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1360000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	955000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
CY2014Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	8000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1413000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1444000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	382000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	332000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268066000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-271328000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	929000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	441000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	491000	USD
CY2013Q1	us-gaap	Stock Issued1 StockIssued1	133000	USD
CY2014Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	38873	shares
CY2013	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	486923	shares
CY2014Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1641000	USD
CY2014Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	42000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	10972000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	8890000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37872179	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30178265	shares
CY2014Q1	apri	Business Acquisition Contingent Consideration At Fair Value Noncurrent1 BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent1	1000000	USD
CY2013Q4	apri	Business Acquisition Contingent Consideration At Fair Value Noncurrent1 BusinessAcquisitionContingentConsiderationAtFairValueNoncurrent1	0	USD
CY2014Q1	apri	Deliverables In Arrangement DeliverablesInArrangement	2	deliverable
CY2014Q1	apri	Increase Decrease In Deferred Revenue Long Term IncreaseDecreaseInDeferredRevenueLongTerm	1000000	USD
CY2013Q1	apri	Increase Decrease In Deferred Revenue Long Term IncreaseDecreaseInDeferredRevenueLongTerm	0	USD
CY2013Q1	apri	Increase Decreasein Deferred Revenue Short Term IncreaseDecreaseinDeferredRevenueShortTerm	-32000	USD
CY2014Q1	apri	Increase Decreasein Deferred Revenue Short Term IncreaseDecreaseinDeferredRevenueShortTerm	3654000	USD
CY2013Q1	apri	Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Amount NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationAmount	0	USD
CY2014Q1	apri	Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Amount NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationAmount	42000	USD
CY2013Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	298000	USD
CY2014Q1	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	515000	USD
CY2014Q1	apri	Short Term Liability Arising From Deconsolidation Of French Subsidiaries ShortTermLiabilityArisingFromDeconsolidationOfFrenchSubsidiaries	2846000	USD
CY2013Q4	apri	Short Term Liability Arising From Deconsolidation Of French Subsidiaries ShortTermLiabilityArisingFromDeconsolidationOfFrenchSubsidiaries	2846000	USD
CY2014Q1	apri	Stock Returned From Contract Settlement Value StockReturnedFromContractSettlementValue	910000	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37855072	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
CY2014Q1	dei	Trading Symbol TradingSymbol	APRI

Files In Submission

Name	View Source	Status
0001017491-14-000070-index-headers.html	Edgar Link	pending
0001017491-14-000070-index.html	Edgar Link	pending
0001017491-14-000070.txt	Edgar Link	pending
0001017491-14-000070-xbrl.zip	Edgar Link	pending
apri-20140331.xml	Edgar Link	completed
apri-20140331.xsd	Edgar Link	pending
apri-20140331_cal.xml	Edgar Link	unprocessable
apri-20140331_def.xml	Edgar Link	unprocessable
apri-20140331_lab.xml	Edgar Link	unprocessable
apri-20140331_pre.xml	Edgar Link	unprocessable
apri-201433110xq.htm	Edgar Link	pending
apri-2014331xex311.htm	Edgar Link	pending
apri-2014331xex312.htm	Edgar Link	pending
apri-2014331xex321.htm	Edgar Link	pending
apri-2014331xex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEEL
Seelos Therapeutics Inc Stock $seel

2014 Q1 Form 10-Q Financial Statement

#000101749114000070 Filed on May 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL Seelos Therapeutics Inc Stock $seel

2014 Q1 Form 10-Q Financial Statement

#000101749114000070 Filed on May 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEEL
Seelos Therapeutics Inc Stock $seel